Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15554800 | 0.82 | HCAR2 (0.35) | HCAR2MAP4K1L3MBTL1JAK1FLT3 | |
| SCHEMBL31467466 | 0.81 | HCAR2 (0.38) | HCAR2DYRK1AKITPDE4D | |
| SCHEMBL30300526 | 0.80 | HCAR2 (0.63) | HCAR2MAP4K1KITJAK1FLT3 | |
| SCHEMBL4631308 | 0.76 | HCAR2 (0.63) | HCAR2DYRK1A | |
| SCHEMBL31162505 | 0.74 | HCAR2 (0.50) | HCAR2DYRK1AKITL3MBTL1PDE4D | |
| SCHEMBL30863956 | 0.72 | HCAR2 (0.44) | HCAR2DYRK1AKITPDE4D | |
| SCHEMBL17675180 | 0.72 | SMN1; SMN2 (0.42) | FLT3 | |
| SCHEMBL16453474 | 0.71 | KDM4C (0.53) | HCAR2DYRK1AKITL3MBTL1PDE4D | |
| SCHEMBL19158730 | 0.68 | PDE4D (0.59) | HCAR2KITPDE4D | |
| SCHEMBL22900562 | 0.66 | PDE4D (0.47) | HCAR2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | FASN, FADS1, COASY | HCAR2 363/4885DYRK1A 3689/4885MAP4K1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.